Corbus Pharmaceuticals Reports First Quarter Financial Results and Corporate Updates
May 11, 2020 07:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Topline results for lenabasum Phase 3 RESOLVE-1 study in systemic sclerosis remain on schedule for summer of 2020, followed by Phase 2b study data in cystic fibrosis Phase 1 trial of CRB-4001 remains...